The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Results from CC-92480-MM-001: mezigdomide combined with dexamethasone in R/R multiple myeloma
In this video, Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, highlights findings of the ongoing Phase I/II dose expansion study of mezigdomide combined with dexamethasone for relapsed/refractory (R/R) multiple myeloma (MM). Overall, it was found that mezigdomide plus dexamethasone had a manageable safety profile and demonstrated durable efficacy in patients with triple-class refractory disease, including those treated with prior BCMA-targeting therapies. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
